Last reviewed 2026-05-27 · How we verify

microsurfaced split thickness skin graft

CellTherX · FDA-approved active Biologic Under review

microsurfaced split thickness skin graft is a Biologic drug developed by CellTherX. It is currently FDA-approved for Acute and chronic wound coverage, Burn wounds, Traumatic wounds requiring skin grafting.

A microsurfaced split thickness skin graft is a processed autologous skin tissue product that provides a scaffold for wound healing and tissue regeneration.

Microsurfaced split thickness skin graft is a type of skin graft used to treat burns and wound healing. It has been studied in clinical trials, including a prospective, randomized study to evaluate its effectiveness in deep burn wounds.

At a glance

Generic name	microsurfaced split thickness skin graft
Sponsor	CellTherX
Modality	Biologic
Therapeutic area	Wound Care / Dermatology
Phase	FDA-approved

Mechanism of action

This product takes a patient's own split thickness skin and applies microsurfacing technology to enhance the graft's integration and healing properties. The microsurfacing modifies the graft surface to improve cell adhesion, vascularization, and incorporation into the wound bed, promoting faster and more effective wound closure and tissue repair.

Approved indications

Acute and chronic wound coverage
Burn wounds
Traumatic wounds requiring skin grafting

Common side effects

Graft failure or poor integration
Infection at graft site
Scarring or contracture
Donor site complications

Key clinical trials

Microsurfaced Grafts in Deep Burn Wounds (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

microsurfaced split thickness skin graft CI brief — competitive landscape report
microsurfaced split thickness skin graft updates RSS · CI watch RSS
CellTherX portfolio CI

Frequently asked questions about microsurfaced split thickness skin graft

What is microsurfaced split thickness skin graft?

microsurfaced split thickness skin graft is a Biologic drug developed by CellTherX, indicated for Acute and chronic wound coverage, Burn wounds, Traumatic wounds requiring skin grafting.

How does microsurfaced split thickness skin graft work?

A microsurfaced split thickness skin graft is a processed autologous skin tissue product that provides a scaffold for wound healing and tissue regeneration.

What is microsurfaced split thickness skin graft used for?

microsurfaced split thickness skin graft is indicated for Acute and chronic wound coverage, Burn wounds, Traumatic wounds requiring skin grafting.

Who makes microsurfaced split thickness skin graft?

microsurfaced split thickness skin graft is developed and marketed by CellTherX (see full CellTherX pipeline at /company/celltherx).

What development phase is microsurfaced split thickness skin graft in?

microsurfaced split thickness skin graft is FDA-approved (marketed).

What are the side effects of microsurfaced split thickness skin graft?

Common side effects of microsurfaced split thickness skin graft include Graft failure or poor integration, Infection at graft site, Scarring or contracture, Donor site complications.

Manufacturer: CellTherX — full pipeline
Therapeutic area: All drugs in Wound Care / Dermatology
Indication: Drugs for Acute and chronic wound coverage
Indication: Drugs for Burn wounds
Indication: Drugs for Traumatic wounds requiring skin grafting

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing